standard-title Studi Clinici

Studi Clinici

Titolo Fase Stato Sede patologia Strutture coinvolte Dettaglio

TROPION-Breast05 A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

III

in corso

CARCINOMA MAMMARIO

- SC Oncologia Clinica Sperimentale di Senologia

AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 2 STUDY OF THE ATR INHIBITOR TUVUSERTIB IN COMBINATION WITH THE PARP INHIBITOR NIRAPARIB OR THE ATM INHIBITOR LARTESERTIB IN PARTICIPANTS WITH BRCA MUTANT AND/OR OMOLOGOUS RECOMBINATION DEFICIENCY HRD)‑POSITIVE EPITHELIAL OVARIAN CANCER THAT PROGRESSED ON PRIOR PARP INHIBITOR THERAPY

II

in corso

CANCRO OVARICO

- SC Oncologia Clinica Sperimentale Uro - Ginecologica

STUDIO DI REAL-EVIDENCE SU PAZIENTI AFFETTI DA CARCINOMA DEL COLON-RETTO METASTATICO (MCRC) CON MUTAZIONE BRAFV600E IN ITALIA: UNO STUDIO PROSPETTICO NON INTERVENTISTICO

NA

in corso

Cancro del colon-retto

- SC Oncologia Clinica Sperimentale Addominale

A PHASE 3 RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR PARTICIPANTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (TROFUSE-020/GOG-3101/ENGOT-CX20)

III

in corso

CANCRO CERVICE

- SC Oncologia Clinica Sperimentale Uro - Ginecologica

A PHASE 3 STUDY OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN/TAXANE (PACLITAXEL OR NAB-PACLITAXEL) FOLLOWED BY PEMBROLIZUMAB WITH OR WITHOUT MAINTENANCE MK-2870 IN THE FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER

III

in corso

TUMORE DEL POLMONE NON A PICCOLE CELLULE

- SC Oncologia Clinica Sperimentale Toraco - Polmonare